Maria Josep Carreras Soler I graduated in Pharmacy from the UB (1986) with an Extraordinary Degree Award (1986). I specialized in Hospital Pharmacy at the Vall d’Hebron University Hospital (1989), and later I obtained the American Board Certified Oncology Pharmacist accreditation granted by the Board of Pharmaceutical Specialties (1999). I obtained my Doctorate in Medicine from the UAB in Barcelona (2020). I am currently Head of the Pharmacy Service Section and responsible for the Pharmaceutical Care Unit for Oncohematological Patients. Instituciones de las que forman parte Investigador predoctoral Investigación en Farmacia Básica, Traslacional y Clínica Vall Hebron Institut de Recerca Farmacia Hospital General Cap de Secció Farmàcia Serveis transversals Twitter Maria Josep Carreras Soler Twitter Instituciones de las que forman parte Investigador predoctoral Investigación en Farmacia Básica, Traslacional y Clínica Vall Hebron Institut de Recerca Farmacia Hospital General Cap de Secció Farmàcia Serveis transversals I graduated in Pharmacy from the UB (1986) with an Extraordinary Degree Award (1986). I specialized in Hospital Pharmacy at the Vall d’Hebron University Hospital (1989), and later I obtained the American Board Certified Oncology Pharmacist accreditation granted by the Board of Pharmaceutical Specialties (1999). I obtained my Doctorate in Medicine from the UAB in Barcelona (2020). I am currently Head of the Pharmacy Service Section and responsible for the Pharmaceutical Care Unit for Oncohematological Patients.
My healthcare activity is focused on ensuring effective and safe pharmacotherapy for patients undergoing antineoplastic treatment for an oncological or hematological tumor. Also ensuring environmental safety and the safety of professionals who work handling biohazardous drugs in this context. I have been part of the hospital's Oncology Commission for years, as well as other intra- and extra-hospital working groups or commissions that generally aim to achieve good use of antineoplastic drugs. In the collaborative field, I am a founding member and have held various positions in the cooperative group in Oncology Pharmacy (GEDEFO) of the Spanish Society of Hospital Pharmacy (SEFH). Teaching is an area in which I am actively involved. I am responsible for the training area in oncohematological pharmacy at the SEFH, and I have directed the national course for hospital pharmacists to obtain the American BPS-BCOP accreditation since its first edition in 2002. I am part of the VHIR research group in basic, translational and clinical pharmacy, in which my work focuses on the study of the use of oncohematological drugs for the treatment of tumors, the development of management and traceability programs for the antineoplastic process and the robotization of their preparation.
Proyectos OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE ANTÍGENO QUIMÉRICO (CAR-T) IP: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE Colaboradores: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE , Gloria Inés Iacoboni García-Calvo, Maria Queralt Gorgas Torner, Lucas Rivera Sánchez, Anna Maria Farriols Danes, Pere Barba Suñol, Carla Alonso Martinez, Janire Perurena Prieto, Maria Josep Carreras Soler, Cecilia Carmen Carpio Segura Entidad financiadora: Instituto de Salud Carlos III Financiación: 111320 Referencia: PI21/00197 Duración: 01/01/2022 - 31/12/2024 Desenvolupament i validació d'un mètode per a la determinació simultània dels citostàtics més prescrits en un hospital de tercer nivell IP: - Colaboradores: Elena García Arumí, Ramon Martí Seves, Maria Josep Carreras Soler Entidad financiadora: Col·legi de Farmacèutics de Barcelona Financiación: 9000 Referencia: COFB-2012-01 Duración: 18/06/2012 - 17/06/2013 Calidad y seguridad en la utilización de factores estimulantes de la eritropoyesis en pacientes con cáncer sólido. Estudio observacional retrospectivo multicéntrico. IP: Maria Josep Carreras Soler Colaboradores: Maria Rosa Gómez Domingo, Anna Maria Farriols Danes Entidad financiadora: Ministerio Sanidad Financiación: 40000 Referencia: EC10-334 Duración: 01/01/2011 - 31/05/2012 Estudiio fase II prospectivo, abierto, multicéntrico de Gemcitabina y Oxaliplatino + Rituximab en pacientes con linfomas agresivos (difuso de células grandes B y del manto) en recaída o resistencia no subsidiarios de ser sometidos a quimioterapia intensa IP: - Colaboradores: J. Bruno Montoro Ronsano, Mercedes Gironella Mesa, Maria Josep Carreras Soler Entidad financiadora: Instituto de Salud Carlos III Financiación: 751410 Referencia: EC08/00140 Duración: 01/01/2009 - 30/06/2014
